Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 67 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016', provides in depth analysis on Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted pipeline therapeutics. 

The report provides comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF-8), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 (Myostatin or GDF-8)
- The report reviews Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 (Myostatin or GDF-8)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Growth/Differentiation Factor 8 (Myostatin or GDF-8) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Growth/Differentiation Factor 8 (Myostatin or GDF-8) Overview 7
Therapeutics Development 8
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Products under Development by Stage of Development 8
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Products under Development by Therapy Area 9
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Products under Development by Indication 10
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Products under Development by Companies 13
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Companies Involved in Therapeutics Development 21
Acceleron Pharma, Inc. 21
Atara Biotherapeutics, Inc. 22
Bristol-Myers Squibb Company 23
Eli Lilly and Company 24
Milo Biotechnology LLC 25
Pfizer Inc. 26
Regeneron Pharmaceuticals, Inc. 27
Sarepta Therapeutics, Inc. 28
Scholar Rock, Inc. 29
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Drug Profiles 30
AAV1-Foliistatin - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
AAV9-Follistatin - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
ACE-083 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
ACE-2494 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
ACE-2798 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
ATA-842 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
BMS-986089 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
domagrozumab - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
landogrozumab - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
luspatercept - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
OSX-200 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
SRK-015 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
trevogrumab - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Dormant Projects 52
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Discontinued Products 53
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Featured News & Press Releases 54
May 19, 2016: Acceleron Announces Data Presentations with Luspatercept at the 21st Congress of the European Hematology Association 54
May 09, 2016: Follistatin Gene Therapy Increases Function in Inclusion Body Myositis Patients 55
Dec 07, 2015: FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Lower-Risk Myelodysplastic Syndromes 55
Dec 05, 2015: Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Myelodysplastic Syndromes Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition 56
Dec 01, 2015: Acceleron Announces Oral Plenary Presentation for ACE-083 in the Late Breaking Clinical Trials Session at the 8th International Conference on Cachexia, Sarcopenia and Muscle Wasting 57
Nov 05, 2015: Acceleron Announces New Data on Luspatercept at the 2015 American Society of Hematology Annual Meeting 57
Oct 23, 2015: Acceleron Highlights Phase 3 Studies, New Clinical Results and Research Strategies at Research and Development Day Event 58
Oct 01, 2015: Acceleron Presents Preclinical Data for ACE-083 at the 20th International Annual Congress of the World Muscle Society 59
Oct 01, 2015: Acceleron Presents Preclinical Data for ACE-2494 at the 20th International Annual Congress of the World Muscle Society 60
Sep 23, 2015: Scholar Rock Presents First Data for Niche Modulator Inhibiting Myostatin Activation and Announces SRK-015 as Lead Drug Program 60
Jun 12, 2015: Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association 61
Jun 09, 2015: Acceleron Pharma to Host Conference Call and Webcast to Review New Luspatercept Data Presented at the 20th Congress of the European Hematology Association 62
May 21, 2015: Acceleron to Present Luspatercept Clinical Trials at the 20th Congress of the European Hematology Association 63
May 18, 2015: FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-Thalassemia 63
May 02, 2015: Luspatercept Data Presented at the 13th International Symposium on Myelodysplastic Syndromes 64
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67

List of Tables

Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Products under Development by Companies, H1 2016 14
Assessment by Monotherapy/Combination Products, H1 2016 15
Number of Products by Stage and Mechanism of Action, H1 2016 16
Number of Products by Stage and Route of Administration, H1 2016 18
Number of Products by Stage and Molecule Type, H1 2016 20
Pipeline by Acceleron Pharma, Inc., H1 2016 21
Pipeline by Atara Biotherapeutics, Inc., H1 2016 22
Pipeline by Bristol-Myers Squibb Company, H1 2016 23
Pipeline by Eli Lilly and Company, H1 2016 24
Pipeline by Milo Biotechnology LLC, H1 2016 25
Pipeline by Pfizer Inc., H1 2016 26
Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 27
Pipeline by Sarepta Therapeutics, Inc., H1 2016 28
Pipeline by Scholar Rock, Inc., H1 2016 29
Dormant Projects, H1 2016 52
Discontinued Products, H1 2016 53